Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

61.24 -0.08 (-0.13%)
Streaming Delayed Price Updated: 12:24 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunocore Holdings Plc ADR

< Previous 1 2 3 Next >
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
Key Takeaways From Immunocore Hldgs Analyst Ratings
Via Benzinga
Immunocore Hldgs's Earnings: A Preview
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst
H.C. Wainwright analyst Patrick R. 
Via Benzinga
5 Analysts Have This to Say About Immunocore Hldgs
Via Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
--News Direct-- 
Via News Direct
Analyst Ratings for Immunocore Hldgs
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Expectations for Immunocore Hldgs's Future
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Immunocore Hldgs's Earnings Outlook
Via Benzinga
Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Expert Ratings for Immunocore Hldgs
Via Benzinga
Recap: Immunocore Hldgs Q1 Earnings
Via Benzinga
Short Volatility Alert: Immunocore Hldgs
On Friday, shares of Immunocore Hldgs (NASDAQ: IMCR) experienced volatile short activity. After the activity, the stock price went up +3.38% to $54.81. The overall sentiment for IMCR has been Bearish. 
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.